Strontium-89

Strontium-89 (Template:SimpleNuclide) is a radioactive isotope of strontium produced by nuclear fission, with a half-life of 50.57 days. It undergoes β⁻ decay into yttrium-89. Strontium-89 has an application in medicine.<ref>Template:Cite journal</ref>

History

Strontium-89 was first synthesized in 1937 by D. W. Stewart et al. at the University of Michigan; it was synthesized via irradiation of stable strontium (⁸⁸Sr) with deuterons.<ref name=discovery>Template:Cite journal</ref> Biological properties and applications of strontium-89 were studied for the first time by Belgian scientist Charles Pecher.<ref>Template:Cite journal</ref><ref name=":2">Template:Cite book</ref> Pecher filed a patent in May 1941 for the synthesis of strontium-89 and yttrium-86 using cyclotrons, and described the therapeutic use of strontium.<ref>Template:Cite patent</ref>

Physiological effects and medical use

File:Metastron (Strontium-89), GE Healthcare.jpg

CitationClass=web }}</ref>

Strontium belongs to the same periodic family as calcium (alkaline earth metals), and is metabolised in a similar fashion, preferentially targeting metabolically active regions of the bone. ⁸⁹Sr is an artificial radioisotope used in the treatment of osseous (bony) metastases of bone cancer.<ref name="HalperinPerez2008">Template:Cite book</ref><ref name="BaumanCharette2005">Template:Cite journal</ref>

In circumstances where cancer patients have widespread and painful bony metastases, the administration of ⁸⁹Sr results in the delivery of beta particles directly to the area of bony problem, where calcium turnover is greatest.<ref name="MertensFilipczak1998">Template:Cite journal</ref> Consequently, intravenous or intracavity administration of ⁸⁹Sr may be helpful in the palliation of painful bony metastases, as it allows radiation to be targeted at metastatic lesions, inducing apoptosis of cells, membrane and protein damage. Subsequently, bone pain resulting from cytokine release at the site of lesions, bone-associated nerve compression and stretching of the periosteum may be reduced. Treatment with ⁸⁹Sr has been particularly effective in patients with hormonally-resistant prostate cancer, often leading to a decreased requirement for opioid analgesics, an increase in time until further radiation is needed, and a decrease in tumour markers.

See also

• Isotopes of strontium
• Alpharadin, radium-223 with similar clinical use